EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 339 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR 如何捐赠头发来帮助癌症患者 April 13, 2022 ¿Qué es la escasez de medicamentos y cómo puede afectar a... June 30, 2023 EMA Recommends Extension of Therapeutic Indications for Osimertinib April 26, 2021 How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 Load more HOT NEWS World No Tobacco Day 2024: European Societies call for an EU... Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... Man Met A Stranger At A Bar Who Was In Need... Cancer Research UK thanks Tania Bryer for a decade of fundraising...
